Results 221 to 230 of about 1,742,061 (410)

Optogenetic‐Controlled iPSC‐Based Vaccines for Prophylactic and Therapeutic Tumor Suppression in Mice

open access: yesAdvanced Science, EarlyView.
This study develops an a red/far‐red light‐controlled iPSC‐based vaccines (RIVA) based on the chimeric photosensory protein FnBphP and its interaction partner LDB3 for cancer immunotherapy. The RIVA preserves the multiple intrinsic tumor antigens of iPSCs and enables optogenetic control of the expression of the immune adjuvant type I interferon β under
Longliang Qiao   +17 more
wiley   +1 more source

“Somatic” and “pathogenic” - is the classification strategy applicable in times of large-scale sequencing?

open access: yesHaematologica, 2019
Constance Baer   +7 more
doaj   +1 more source

LEDGF Binds H3R17me2a Promoting De Novo Nucleotide Biosynthesis in SETD2 Mutant Clear Cell Renal Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
In SETD2‐mutant ccRCC, the original LEDGF recognition of the H3K36me3 regulatory axis no longer exists. LEDGF interacts with CARM1‐dependent H3R17me2a regulating the transcription of key enzymes in the de novo synthesis pathway. The abnormally elevated LEDGF leads to the accumulation of purine nucleotides in SETD2‐mutant ccRCC, thereby satisfying the ...
Yuwei Zhang   +11 more
wiley   +1 more source

P763: VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS

open access: yesHemaSphere, 2022
S. P. Desikan   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy